Chiglitazar: First Approval

Chiglitazar monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomized, double-blind, phase 3 trial (CMAS)

(2021) Weiping Jia et al.   Science Bulletin

Efficacy and safety of chiglitazar, a novel peroxisome proliferator-activated receptor pan-agonist, in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, phase 3 trial (CMAP)

(2021) Linong Ji et al.   Science Bulletin

To Probe Full and Partial Activation of Human Peroxisome Proliferator-Activated Receptors by Pan-Agonist Chiglitazar Using Molecular Dynamics Simulations

(2020) Holli-Joi Sullivan et al.   PPAR Research

Pharmacokinetics and Safety of Chiglitazar, a Peroxisome Proliferator‐Activated Receptor Pan‐Agonist, in Patients < 65 and ≥ 65 Years With Type 2 Diabetes

(2020) Xiaojiao Li et al.   Clinical Pharmacology in Drug Development

Pharmacokinetics, Safety and Tolerability of Chiglitazar, A Novel Peroxisome Proliferator-Activated Receptor (PPAR) Pan-Agonist, in Healthy Chinese Volunteers: A Phase I Study

(2019) Hong-Rong Xu et al.   CLINICAL DRUG INVESTIGATION

17-OR: Efficacy and Safety of Chiglitazar, a Novel PPARα/γ/d Pan-Agonist, in Patients with Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Superiority Trial (CMAP)

(2019) LINONG JI et al.   DIABETES

Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence

(2019) Cheng et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Distinct but complementary contributions of PPAR isotypes to energy homeostasis

(2017) Vanessa Dubois et al.   JOURNAL OF CLINICAL INVESTIGATION

Chiglitazar Preferentially Regulates Gene Expression via Configuration-Restricted Binding and Phosphorylation Inhibition of PPARγ

(2017) De-Si Pan et al.   PPAR Research

In VitroandIn VivoCharacterizations of Chiglitazar, a Newly Identified PPAR Pan-Agonist

(2012) B. K. He et al.   PPAR Research